Monoclonal Antibody Therapy Market: Global Market Growth, Trends, and Forecast
The Monoclonal Antibody Therapy Market is experiencing steady expansion as healthcare systems increasingly adopt targeted and personalized treatment approaches. According to Market Research Future, the market was valued at USD 151.25 billion in 2024 and is projected to grow from USD 157.25 billion in 2025 to USD 232.1 billion by 2035, representing a CAGR of approximately 3.9% during the forecast period.
The rising prevalence of chronic diseases, including cancer and autoimmune disorders, is an important factor supporting market growth. Monoclonal antibodies can selectively target specific molecules or cells, making them valuable across several therapeutic applications. Oncology currently represents the largest application segment, while autoimmune diseases are emerging as an important area of growth.
Technological developments in biotechnology and antibody production are further strengthening the industry. Hybridoma technology remains an important production method, while recombinant DNA technology is gaining momentum because of advances in genetic engineering and therapeutic development.
North America currently dominates the market, supported by advanced healthcare infrastructure, strong biotechnology capabilities, and substantial research investments. Meanwhile, emerging markets are creating additional opportunities as healthcare access and biologic adoption expand.
Overall, increasing demand for targeted therapies, personalized medicine, biotechnology innovation, and expanding therapeutic applications are expected to support the continued development of the global Monoclonal Antibody Therapy Market through 2035.